SANTA CLARA, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Chief Financial Officer Dan Puckett plans to retire in the first quarter of 2024. Dan has served […]
Other News
New Study Confirms HeartFlow FFRCT Leads to Improved Patient Outcomes
CLEVELAND – A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart & Vascular Institute, has now shown through a clinical study to significantly decrease cardiovascular mortality, reduce additional non-invasive heart testing, and increase cath lab efficiency. These results show a promising, new approach that […]
LIB Therapeutics Appoints David Cory as Chief Executive Officer as Lead Clinical Programs Achieve Phase 3 Completion
CINCINNATI–(BUSINESS WIRE)–LIB Therapeutics Inc. (LIB), a late-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor therapies for patients at very high and high-risk of cardiovascular disease (CVD), today announced that the Board of Directors has appointed David Cory as Chief Executive Officer and a member of the Board of Directors, […]
Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology
TOKYO–(BUSINESS WIRE)–Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports of two patients in the Phase 1/2 clinical trial (LAPiS Study) of HS-001 in combination with coronary artery bypass grafting surgery for advanced heart failure, was presented by the investigator […]
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting
NEW YORK, Sept. 11, 2023 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the details of an oral presentation by independent investigators on September 9, 2023 at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting held in Copenhagen, Denmark. Uveal […]
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
Exploratory post-hoc analysis of STELLAR shows potential of sotatercept to improve cardiovascular function Interim results from SOTERIA open-label extension study represent longest safety and efficacy analysis of sotatercept to date; safety profile of sotatercept consistent with previous studies and efficacy improvements maintained after one year of therapy Nine Merck-sponsored abstracts […]
CEUS Underutilization May Pose Greater Risk Than Rare Side Effects Associated With Use, Say Experts
CHICAGO–(BUSINESS WIRE)–Contrast enhanced ultrasound (CEUS) is underutilized in the United States, and reduced access to this noninvasive diagnostic imaging tool may pose a greater risk to patients than rare side effects associated with use, according to doctors who spoke today at the 37th International Bubble Conference in Chicago. “CEUS cardiac exam […]
Positron Corporation Announces Start of Clinical Study of Affinity PET-CT Device
Niagara Falls, NY, Sept. 08, 2023 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity™ PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA. […]
Shape Memory Medical Receives FDA IDE Approval to Initiate AAA-SHAPE, a Head-to-Head Trial
SANTA CLARA, Calif.–(BUSINESS WIRE)–Shape Memory Medical Inc., developer of custom shape memory polymers for endovascular markets, announced that the Food and Drug Administration (FDA) granted investigational device exemption (IDE) for the company to begin a prospective, multicenter, randomized, open-label trial to determine safety and effectiveness of the IMPEDE-FX RapidFill® Device […]
Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a New Technology Add-on Payment for the DETOUR System
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announces that the U. S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the DETOUR System, an FDA-designated Breakthrough Device, […]
Recent
MicroTransponder Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
New Minimally Invasive Therapy at MemorialCare Heart & Vascular Institute Reduces Cardiovascular Mortality by Nearly 30% in Patients with Resistant Hypertension
Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
Popular
- No commented posts yet